Highlights d TDP-43 regulates microglial phagocytosis and clearance of Ab d Depletion of microglial TDP-43 results in enhanced synapse loss d Depletion of microglial TDP-43 promotes amyloid clearance in a mouse model of AD d TDP-43 pathology is associated with lower amyloid deposition in post-mortem brains
rosachiara.paolicelli@irem.uzh.ch (R.C.P.), lawrence.rajendran@irem.uzh.ch (L.R.) In Brief Paolicelli et al. show that TDP-43 is a regulator of microglial phagocytosis. They found that mice lacking microglial TDP-43 display enhanced amyloid clearance but also significant synapse loss. They also show that TDP-43 pathology is associated with reduced amyloid burden in human brains.
INTRODUCTION
Microglia, the innate immune cells of the central nervous system (CNS), provide constant surveillance for neural functioning (Nimmerjahn et al., 2005; Davalos et al., 2005) . They coordinate various critical roles throughout life, assisting early neuronal development and circuit formation and maintaining brain homeostasis (Paolicelli and Gross, 2011; Tremblay et al., 2011; Kettenmann et al., 2013) . As the primary source of phagocytes in the CNS, microglia engulf cellular debris upon programmed apoptosis, remove excess synapses during neural circuit maturation, and clear the brain from potentially dangerous protein aggregates (Wakselman et al., 2008; Sierra et al., 2010; Lee and Landreth, 2010; Prinz et al., 2011) . Synapse elimination is activity dependent and strictly confined to the first postnatal weeks in the rodent brain, a physiological process defined as synaptic pruning Schafer et al., 2012) . However, recent studies indicate that this process re-activates in Alzheimer's disease (AD), in which amyloid promotes microglia-mediated removal of synapses (Hong et al., 2016) . Synaptic loss, an early and highly predictive correlate of cognitive decline (Terry et al., 1991) , occurs not only in AD but also in other distinct neurodegenerative disorders characterized by the presence of toxic protein aggregates. This accumulation classifies these disorders as proteinopathies.
Evidence from genome-wide association studies (GWASs) reveals that most genes associated with risk to develop such disorders are highly expressed in microglia, which implies that they could modulate immune and phagocytic functions in disease states (Derecki et al., 2014) . This hypothesis suggests that they may confer susceptibility to develop the diseases by modulating microglia-mediated protein aggregates clearance rather than production. We previously demonstrated that risk genes associated with late-onset AD do not affect amyloid production, which suggests that these predisposing genetic factors contribute to disease development through different mechanisms (Bali et al., 2012) . These data implicate microglia in the pathogenesis of neurodegenerative disorders. However, it remains unknown whether an intrinsic dysfunction in microglia can promote pathological synaptic pruning leading to abnormal synapse loss. intracellularly through enzymatic degradation following phagocytosis or extracellularly through degradation by secreted enzymes (Vekrellis et al., 2000; Nakanishi, 2003; Ries and Sastre, 2016; Solé -Domè nech et al., 2016) . We selected 18 top-ranked genes associated with neurodegenerative diseases and, using a loss-of-function approach, we screened them for their role to modulate microglial clearance of beta amyloid (Ab), a well-established target for microglial phagocytosis and degradation (Paresce et al., 1996; Frenkel et al., 2013) . Among the candidates we tested, TDP-43 exhibited the strongest Ab clearance in BV2 cells, i.e., residual Ab peptide levels measured from medium containing endogenous murine Ab showed a significant reduction after exposure to cells in which TDP-43 gene was knocked down (Figures S1A-S1D). TDP-43 is a 43 kDa DNA-RNA binding protein encoded by the Tardbp gene and is a known transcriptional repressor, mRNA binding protein, and splicing factor (Buratti and Baralle, 2001; Lagier-Tourenne et al., 2010; Polymenidou et al., 2011; Baralle et al., 2013) . Ubiquinated TDP-43 aggregates represent the predominant constituent of cytoplasmic inclusions in glia and neurons in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) patients, who show severe neuronal loss in frontal or motor cortex, respectively (Neumann et al., 2006) . In the last years, the number of neurodegenerative disorders associated with TDP-43 pathology has considerably increased (Cook et al., 2008; Buratti and Baralle, 2009 ). The accompanying cell death in these disorders may arise from a combination of a toxic gain of function and a loss of nuclear TDP-43, both of which are associated with the presence of cytoplasmic aggregates (Cohen et al., 2011; Gendron and Petrucelli, 2011) . Although a gain of toxicity induced by cytoplasmic inclusions can significantly contribute to the pathology Medina et al., 2014; Walker et al., 2015) , TDP-43 loss of function in neurons has been shown to be sufficient for inducing neuronal loss, accompanied by neuropathological alterations (Kraemer et al., 2010; Wu et al., 2012; Iguchi et al., 2013; Vanden Broeck et al., 2013) . However, no evidence so far existed to support a role for loss of TDP-43 in microglia in the pathogenesis of the disease.
We wanted to confirm whether the enhanced clearance observed upon Tardbp knockdown could be also replicated with human Ab. To this end, TDP-43-depleted BV2 cells were incubated overnight with conditioned medium derived from HeLa cells overexpressing the Swedish mutation of the human Amyloid Precursor Protein (sweAPP). This assay ensured that BV2 cells were exposed to medium containing high levels of human Ab. Consistent with our findings from the murine Ab screen, TDP-43 depletion resulted in a higher clearance capacity of all the Ab species measured, compared to a scrambled control ( Figure 1A ). We achieved efficient TDP-43 depletion using either siRNA pools or single oligos ( Figure 1B) , with consistent results on amyloid clearance ( Figure S1E ).
To determine whether enhanced phagocytosis was the mechanism that mediated this enhanced clearance, we measured the internalization of fluorescently labeled Ab peptide, a cargo previously reported to be phagocytosed by microglia (Paresce et al., 1996) . In a validation experiment, the internalization of the Ab peptide was followed in time lapse with the pH-dependent Lyso-Tracker dye, to ensure that the cargo was trafficked to intracellular acidic compartments (Movie S1; Figurea S2A and S2B). TDP-43 depletion significantly enhanced intracellular levels of fluorescent Ab ( Figures 1C and 1D ). Consistent with the enhanced uptake, we found a similar effect using fluorescently labeled dextran (Figures 1E and 1F) and transferrin (Figures 1G and 1H) , which target uptake-mediated cargo. These results indicate that TDP-43 depletion in microglia increases the overall phagocytic activity.
Next, we determined whether the increased uptake was functionally followed by enhanced intracellular degradation. For that, we quantified the fluorescent signal of internalized Ab40 3 hr after the uptake (T = 3 hr) and found a significant reduction in intracellular fluorescence, despite a higher uptake as measured by the initial amount (T = 0 hr) ( Figures 1I and 1J ). Since TDP-43 depletion increased intracellular degradation and amyloid is sorted to the lysosomal compartment for degradation in microglia (Cole et al., 1992) , we examined whether increased lysosomal function occurs after TDP-43 depletion. We found higher levels of acidic late endosomal/lysosomal structures indicated by the pH-sensitive LysoTracker staining ( Figures 1K and 1L ). In addition, increased levels of lysosomal markers, such as LAMP1 and LAMP2, also accompanied the increased changes in acidic organelles in both BV2 cells ( Figure 1M ) and primary microglia cultures depleted of TDP-43 ( Figures S3A-S3C ). TDP-43 loss was recently shown to promote the nuclear translocation of TFEB, a transcription factor regulating lysosomal biogenesis . To investigate whether this was the case in microglia cells depleted of TDP-43, we assessed a subset of CLEAR (coordinated lysosomal expression and regulation) genes transcripts, downstream of TFEB, by RT-PCR. We found that the expression of Lamp1, CtsD, CtsB, Clcn7, vATP6v1h, Psap, and Psen2 in TDP-43-depleted cells was higher than in scrambled control ( Figure S3D ). Overall, these data identify and validate TDP-43 as a regulator of microglial phagocytosis and clearance of Ab.
Conditional Microglial TDP-43 Depletion In Vivo Promotes Phagocytosis of Stereotactically Injected Ab
We then determined the physiological relevance of these findings in vivo by generating a microglial-specific inducible conditional TDP-43 knockout mouse line (cKO). We crossed mice expressing tamoxifen-inducible CRE recombinase (CreER) under the control of the endogenous Cx3cr1 microgliaspecific promoter (Cx3cr1 creER-YFP ; Parkhurst et al., 2013 ) with *p < 0.05, **p < 0.01 versus scrambled control; ####p < 0.0001 Tardbp siRNA-T3 hr versus Tardbp siRNA-T0, using two-way ANOVA, followed by Bonferroni multiple comparison test. (K and L) Representative confocal images of LysoTracker staining (K) and relative mean intensity quantification in control (n = 33) and TDP-43-depleted BV2 cells using siRNA Tardbp pool oligos, n = 36 or siRNA best 2 oligos, n = 36 (L). Data are shown as mean ± SEM, **p < 0.01, ****p < 0.0001, using one-way ANOVA followed by Dunnett's post hoc test. (M) Representative blots for late endosomal/lysosomal markers in control and Tardbp knockdown BV2 cells.
Tardbp floxed mice (Chiang et al., 2010) (Figure 2A ). We confirmed that Tardbp transcript levels were significantly downregulated specifically in microglia isolated from cKO mice upon tamoxifen administration compared to WT controls, whereas overall cortical levels remained unchanged ( Figures S4A and S4B ). In addition, nuclear TDP-43 depletion was also confirmed at the protein level, in CRE-treated microglial primary cultures prepared from Tardbp floxed mice ( Figures S4C and S4D ).
We then confirmed enhanced phagocytic uptake upon TDP-43 depletion in vivo by injecting Ab42 oligomers in the cortex (100 mM, as prepared in Fa et al., 2010) and quantifying amyloid uptake 24 hr later ( Figures 2B-2E ). Interestingly, we observed a significant increase of microglia cells in close proximity to the amyloid core in cKO mice compared to WT littermates, whereas no differences occurred in the area surrounding the Ab core ( Figures 2D and 2F) . (E and F) Quantification of microglia processes and Ab engulfment surrounding or within amyloid core injection. Data are shown as mean ± SEM from WT, n = 8, and cKO, n = 7, stacks, acquired from n = 3 animals per genotype, *p < 0.05, **p < 0.01, using two-way ANOVA followed by uncorrected Fisher's LSD test.
Conditional Depletion of Microglial TDP-43 Enhances Amyloid Clearance but Also Exacerbates Synaptic Loss in a Mouse Model of AD
In the light of all our findings indicating that TDP-43 depletion in microglia enhances the phagocytic uptake of Ab, we hypothesized that this would promote clearance to reduce the total amyloid burden in a mouse model of AD. To this end, we crossed our Cx3cr1 CreER ;Tardbp floxed mice with mice overexpressing human APP carrying the Arctic and Swedish mutations (APP arc , Knobloch et al., 2007) . Again, in this mouse model of AD, Ab levels measurement revealed a significant reduction in cKO;APP arc compared to WT;APP arc littermates ( Figure 3A ) in the SDS fraction of brain homogenates and showed a similar trend in the TBS fraction ( Figures S5A and S5B ), confirming our in vitro results that TDP-43 depletion in microglia enhanced Ab clearance. We found no differences in sAPPb levels, a soluble intermediate product in the generation of Ab, indicating that the amyloidogenic processing of APP was not affected, as also suggested by comparable levels of the full-length APP ( that TDP-43 depletion in microglia promotes Ab clearance, rather than affecting production. To investigate whether the enhanced Ab clearance had any bearing on the amyloid load, we performed ThioS staining and observed a significant reduction in the cortex of cKO;APP arc mice compared to WT ( Figures 3B-3D) , with no change in plaque size ( Figure S5D ). Levels of Iba1 and CD45 markers in microglia surrounding the plaques were comparable in cKO and WT controls ( Figures S5E-S5G ).
Since amyloid oligomers and plaques are considered the primary cause of synaptotoxicity in AD patients, we hypothesized that enhancing microglial-mediated amyloid clearance should preserve synapses. To our surprise, despite the reduction in amyloid load, we found a significant decrease in cortical synaptic markers in these mice as assayed by western blot ( Figure 3E ). Specifically, PSD95, a scaffold protein located in dendritic spines, was significantly reduced ( Figure 3F ), while levels of MAP2, a dendritic structural protein, were comparable between WT and cKO mice. These results suggest a specific reduction in dendritic spines rather than a general decrease in neuronal branches ( Figure 3G ). Consistently, levels of synapsin and synaptophysin were also reduced ( Figures 3H and 3I ). In addition, quantification of immunoreactive puncta for the synaptic marker vGlut1 also confirmed a drastic reduction in glutamatergic terminals ( Figures 3J and 3K) . These data show that microglia lacking TDP-43 can mediate enhanced removal and clearance of amyloid in an AD mouse model, but also in parallel, induce significant synapse loss. Overall these findings suggest that abnormally phagocytic microglia remove not only amyloid but also synapses.
In Vivo Depletion of TDP-43 from Microglia Results in Enhanced Synapse Loss Even in the Absence of Amyloid Microglia are shown to re-activate synaptic pruning in the presence of Ab oligomers (Hong et al., 2016) . Since we observed synapse loss in mice depleted of microglial TDP-43 in APP transgenic model, we next asked whether amyloid is required for the synapse loss to occur.
To answer this question, we quantified the levels of synaptic markers in the cortex of WT and cKO mice where no human APP gene was overexpressed and thus no amyloid load was present. Here again, we found a significant decrease in vGlut1 and PSD95 ( Figures 4A-4C ). Since demyelination can occur in many neurodegenerative disorders, we also assayed levels of myelinbinding protein (MBP) isoforms and found a significant decrease ( Figures 4A and 4D ). The decrease in PSD95 was significant despite no changes in MAP2 levels, indicative of a selective synapse loss rather than general neuronal death ( Figures 4A and 4E ). Consistent with these findings, we observed a significant decrease in cortical dendritic spine density in cKO mice (Figures 4F and 4G) . vGlut1 immunohistochemistry also revealed a significant decrease in mice depleted of microglial TDP-43 compared to controls ( Figures 4H and 4I) . These results conclusively show that synapse loss occurs due to microglial TDP-43 depletion in mice, independent of amyloid load.
To directly assess the role of microglia in synapse elimination in these mice, we quantified synapse engulfment through 3D reconstruction of confocal acquisitions. Since we observed syn-aptic immunoreactive puncta within CD68-positive phagocytic structures inside microglia cells ( Figure S6 ), our signal co-localization was specific. We then quantified PSD95 immunoreactive puncta within and surrounding microglia cells. There was a significant increase in the fraction of synaptic marker engulfed by TDP-43 depleted microglia compared to WT controls ( Figures  4J and 4K) . We also observed a significant increase in the phagocytic marker CD68 ( Figure 4L ). The cells had increased size and total volume of CD68-positive structures, despite no change in number of structures ( Figures 4M-4O ). Overall, these data show that abnormal microglial phagocytosis induced by TDP-43 depletion mediates synapse loss, regardless of the presence of amyloid.
TDP-43 Pathology Is Associated with Lower Prevalence of AD and Higher Microglial Phagocytic Markers in Postmortem Human Brains
In line with our findings, we predicted that enhanced microgliamediated clearance would affect cognitive decline by targeting synapses yet simultaneously reducing amyloid plaque load. This dual function could complicate the diagnosis of AD, which has been a topic of discussion for a very long time-whether amyloid load correlates with the cognitive decline (Braak and Braak, 1998; Serrano-Pozo et al., 2011; Nelson et al., 2012) . We evaluated the prevalence of AD in a large cohort (n = 698) of ALS patients that typically exhibit TDP-43 pathology (Table S1 ). We selected an age cutoff of 65 years or older, as individuals over the age of 65 are at increased risk of sporadic AD. The prevalence of AD in ALS patients aged 65 to 74 years was comparable to what is expected in the normal population (reference to Hebert et al., 2013) ; however, the AD prevalence was considerably lower in ALS patients aged 75 years and above ( Figure 5A) . Notably, cognitive evaluation revealed a subtle cognitive dysfunction in non-AD ALS patients older than 75 years, despite excluding patients with over-lapping FTLD ( Figure 5B ). These findings suggest that TDP-43 pathology is associated with reduced amyloid burden and may underlie subtle cognitive deficits in non-AD ALS patients. These clinical data support our overall hypothesis that dysfunctional microglia (as due to TDP-43 pathology) can mediate both enhanced amyloid clearance and synapse loss. This suggests that TDP-43 pathology might promote neurodegeneration through synapse loss on one hand, but on the other might also reduce the risk for enhancing the amyloid load and thus decrease the prevalence of AD.
To verify that the observed decreased prevalence of AD in ALS patients is secondary to decreased amyloid burden, we quantified amyloid pathology in an independent brain autopsy cohort, composed of healthy controls, AD cases, and TDP-43 cases (ALS and FTLD-TDP-43). The quantification of Ab was performed using Thal Ab phase (TAP) scoring system. TAP relies on immunohistochemistry and evaluates presence or absence of all Ab plaques spatially across several neocortical, limbic, and subcortical regions of the brain. TAP staging is superior to other methods of Ab quantification in its sensitivity for Ab, as well as prediction of dementia symptoms (Boluda et al., 2014) . Using TAP scoring, we observed Ab plaque burden to be comparable to age-matched controls in 65-to 74-year-old ALS/FTLD-TDP patients. However, similar to how AD prevalence was lower in ALS patients who were 75 years or older, Ab pathology was significantly reduced in the brains collected from ALS/FTLD-TDP patients 75 years or older, compared to the age-matched controls (Figures 5C and 5D ). These findings suggest that TDP-43 pathology might promote enhanced amyloid clearance and hence prevent against AD.
To further validate the increase in the microglial phagocytic marker CD68 observed in our mouse model, we examined an (legend continued on next page) independent brain autopsy cohort. To this end, we tested the levels of cortical CD68 in the context of ALS pathology. Importantly, we found that CD68 burden was significantly higher in ALS patients with TDP-43 pathology as compared to ALS patients without TDP-43 inclusions, or to healthy controls ( Figures  5E and 5F ; Table S2 ), supporting a critical role for TDP-43 in regulating microglial function. Finally, to assess the clinical relevance of the described microglial phenotype, we investigated whether TDP-43 aggregates could be found in the microglia of TDP-43 pathology cases. To this aim, we analyzed eight motor neurodegenerative (MND) cases with TDP-43 pathology and four healthy controls. In the MND cases, but not in the controls, we could observe examples of cytoplasmic inclusions positively stained for phospho-TDP-43 (pTDP-43) within microglial cells positive for Iba1 ( Figure 5G ), indicating that microglial TDP-43 can contribute to TDP-43 pathology. Importantly, though rare, pTDP-43 inclusions in microglia were found in all of the MND cases examined. Overall these findings corroborate the clinical relevance for a dysfunctional, abnormally phagocytic microglial phenotype in TDP-43 pathology.
DISCUSSION
Here we show that loss of TDP-43 in microglia enhances phagocytosis and amyloid clearance following acute Ab oligomers injection and in a mouse model of AD. The abnormal phagocytosis induced by loss of TDP-43 concurrently resulted in an excessive loss of synapses independent of amyloid deposition. Our data demonstrate enhanced lysosomal function following TDP-43 depletion. However, further studies are now required to identify the exact mechanism through which TDP-43 regulates lysosome biogenesis and also enhanced phagocytosis. One possibility is that TDP-43 negatively controls lysosomal biogenesis genes such as the CLEAR genes that are regulated by the transcription factor TFEB. In this study, we found that TDP-43 depletion results in the increase transcription of genes related to lysosomal biogenesis; however, we focused only on a selected set of CLEAR genes. Whether TDP-43 regulates lysosome biogenesis through the entire CLEAR gene network needs to be further elucidated. Alternatively TDP-43 could also regulate mTOR activity, which in turn regulates lysosome biogenesis via the Raptor-TSC2-TFEB-lysosome/autophagosome biogenesis. Recent study performed in HeLa cells showed that TDP-43 loss promotes autophagosomal biogenesis as a direct consequence of decreased Raptor mRNA stability and promotes nuclear translocation of TFEB, a transcription factor master regulator of lysosomal genes . Our findings suggest that TDP-43 depletion positively regulates lysosomal genes downstream of TFEB. However, it remains to be tested whether TDP-43 loss leads to decreased Raptor mRNA and regulation of mTOR activity in microglia cells.
TDP-43 cytoplasmic inclusions can occur in multiple neurodegenerative diseases, which are collectively defined as TDP-43 proteinopathies. This classification highlights a key role for TDP-43 in the disease pathogenesis (Cohen et al., 2011) . Previous studies indicate a causal role for TDP-43 neuronal pathology in the pathogenesis of neurodegeneration and synaptic loss using animal models of disease. These studies suggest, in fact, a cell-autonomous TDP-43 neurotoxicity (Igaz et al., 2011; Xu et al., 2011; Diaper et al., 2013; Yang et al., 2014; Medina et al., 2014; Handley et al., 2016) .
Recent studies revealed additional non-autonomous functions for TDP-43 pathology in Drosophila glia, which result in defective synapses and axonal wrapping of motor neurons (Romano et al., 2015) . However, neither a direct demonstration of microglial TDP-43 function nor its direct contribution to the pathological phenotype has been yet proposed. Here we provide evidence that phosphorylated TDP-43 aggregates can be found in the microglia of human post-mortem brains with TDP-43 pathology, thus opening the possibility that microglial TDP-43 might contribute to the pathogenesis of the disease.
In our model, a microglial-specific dysfunction induced by a loss of TDP-43 mediates a non-cell-autonomous neurotoxic effect, which could sum to other cellular phenotypes and critically contribute to the disorder. However, we cannot exclude the involvement of other Cx3cr1-positive non-parenchymal myeloid cells, considering that Cx3cr1-driven recombination also occurs in perivascular and meningeal macrophages (Goldmann et al., 2016) .
Our data show that abnormal phagocytosis and clearance elicited in microglia following TDP-43 loss is ultimately paradoxical. These processes are not entirely beneficial in the context of a complex organism, since microglial phagocytic activity might not only enable clearance of protein aggregates but also synaptic connection loss. These mixed responses may underlie the failure of many AD drug treatment clinical trials to improve cognitive function, despite the progressive reductions in amyloid burden.
Synaptic pruning by microglia can re-activate in the presence of Ab oligomers, since complement molecules upregulate in the disease state to ultimately mediate synapse removal (Hong et al., 2016) . Here we show that an intrinsic dysregulation of microglia induced by TDP-43 depletion is sufficient to trigger abnormal synapse loss, even in the absence of Ab oligomers. Our results further suggest that microglial dysfunction underlies the pathogenesis of many disparate and distinct neurodegenerative disorders. In line with our results, a recent study reported that selective neuronal depletion of TDP-43 was sufficient to reduce amyloid burden and to exacerbate cognitive deficits in an AD mouse model, suggesting that common mechanisms induced by loss of TDP-43 may partially explain the enhanced amyloid clearance (LaClair et al., 2016) .
(E and F) Representative micrographs for immunostaining against CD68 in cortical section of healthy control, and ALS cases negative and positive for TDP-43 pathology, respectively (E). Relative quantification of CD68 burden in ALS patients with and without TDP-43 pathology indicates increased burden in ALS patients with TDP-43 pathology (F) (mean ± SEM, Control n = 6; *p < 0.05, ALS TDP-43 negative (n = 11) versus ALS TDP-43 positive (n = 16), by using two-tailed unpaired t test); scale bar: 50 mm. Consistent with our experimental findings, we show that the prevalence of AD was considerably reduced in a cohort of ALS patients when compared to the expected AD prevalence in the normal population. Nevertheless, these ALS patients without AD still exhibited a subtle decline in cognitive function, which suggests an underlying loss of synapses. Importantly, neuropathological examination of post-mortem human brains showed a significant reduction of amyloid burden in ALS/FTLD-TDP-43 cases, as compared to age-matched healthy controls. These findings suggest that TDP-43 pathology might lead to enhanced Ab clearance and hence delay AD. However, in the same dataset, a comparison of Ab levels within AD cases with or without TDP-43 pathology did not reveal any major difference. This observation could suggest that the enhanced clearance through TDP-43 pathology might modulate the initial stages of amyloid deposition, but have no effects once the amyloid burden has established. Further studies are required to better elucidate the correlation between AD and TDP-43 pathology.
Indeed, a recent study from a population-based sample revealed a strong association of TDP-43 inclusions with late-onset dementia, but not with AD markers of amyloid and tau (Keage et al., 2014) . Similarly, another study reported that the prevalence of amyloid positivity on PET in FTLD patients was lower than healthy age-matched controls, further corroborating our findings (Ossenkoppele et al., 2015) . Furthermore, reduced amyloid pathology with concomitant exaggerated microglial CD68 levels and activation in TDP-43-positive ALS cases strongly supports our hypothesis (as also observed in Brettschneider et al., 2012) .
Emerging evidence suggests that clearance mechanisms play a crucial role in neurodegenerative disorders, particularly in sporadic cases where no mutations may cause the disease. In addition, genome-wide association studies (GWASs) have identified a growing number of risk factors associated with microglial function. Certainly, identifying the pathways that underlie microgliainduced pathological synaptic pruning is of foremost importance. These pathways could elucidate cellular mechanisms common to the early stages of many distinct neurodegenerative disorders and may also reveal new powerful and efficient therapeutic targets. We believe these interventions could selectively target the paradoxical effects we discovered to prevent synapse loss and cognitive decline.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: executive functioning, semantic fluency, and visuo-spatial functioning as previously described (Jawaid et al., 2010) . Patients were labeled with AD or FTD if their clinical and neuropsychological parameters corresponded to the National Institute of Non-communicable Disorders and Stroke-Alzheimer Disease and Related Disorders Association (NINDS-ADRDA) criteria for probable or possible AD (McKhann et al., 1984) or Neary's criteria for FTD (Neary et al., 1998) respectively. Further details are reported in Table S1 . Informed written consent was obtained from all the patients. The study was approved by the Institutional review board (IRB) of Baylor College of Medicine, Houston, TX, USA.
Human post-mortem study for amyloid detection The autopsy cohort comprised, n = 35 ALS patients with clinical diagnosis of ALS in accordance with the modified El escorial criteria with pathological confirmation of TDP-43 pathology, n = 25 FTLD patients with clinical diagnosis of FTD in accordance with the Neary criteria with pathological confirmation of TDP-43 pathology, n = 40 controls who died of non-neurological causes and were negative for TDP-43 pathology, n = 62 patients with clinically probable AD according to NINDS criteria with pathological confirmation of AD on autopsy. The neuropathological diagnoses were established and documented at the Centre for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania, USA. Informed written consent was obtained from all the patients or their next of kin at the time of death. The autopsies were performed over the course of 22 years and pathological findings, as well as, clinically relevant information (gender, age of onset, site of onset, age at death, disease severity, etc.) were documented in an integrated database described previously .
Human post-mortem study for CD68 and pTDP-43-Iba1 detection The autopsy cohort comprised n = 11 ALS cases TDP-43-negative (average age 66.8 ± 13.13; mean ± SD), n = 16 ALS cases TDP-43 positive (61.6 ± 10.2), and n = 6 healthy control (78.5 ± 0.8) who died of non-neurological causes and were negative for TDP-43 pathology (for details, see Table S2 . Informed written consent was obtained from all the patients or their next of kin at the time of death. Use of human tissue for CD68 post-mortem studies has been reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (11/ES/0022).
METHODS DETAILS
Cell Culture BV2 cells and HeLa cells expressing the APP Swedish mutation (HeLa swAPP) were cultured in DMEM (Invitrogen, CA, USA), supplemented with 10% FCS and 100 U mL-1 penicillin/streptomycin, at 37 C and 5% CO2 in a humidified incubator. In addition, HeLa swAPP were supplemented with 0.1% G418 antibiotic (Carl Roth), and 0.1% Zeocin (Invitrogen). Primary microglial murine cell cultures were prepared as described in Deierborg (2013) . Briefly, mixed glia cultures were prepared from newborn Tardbp floxed/floxed mice and cultured in high glucose (4.5 mg/ml) DMEM + GlutaMax supplemented with 10% FCS and 100 U mL-1 penicillin/streptomycin. Microglial cells were harvested by manual shake-off after 10-14 days of primary cultivation. The medium containing detached microglia was collected and isolated microglia were reseeded on 96-well plates at a density of 4 3 104 cells/well at 37 C and 5% CO2. Cells were allowed to settle for 24 hr before treatment. Tardbp gene deletion was induced in Tardbp floxed/floxed primary microglia culture by recombinant TAT-CRE treatment (100 U/ml medium, EMD Millipore). Control Tardbp floxed/floxed cells were treated with a solution containing 50% glycerol, 500 mM NaCl and 20 mM HEPES at pH 7.4. Cells for immunohistochemistry were seeded onto glass coverslips in 96-well plates. Labeling of acidic organelles in BV2 and primary microglia was performed by incubating living cells, at 37 C and 5% CO2, for 90 min with 200 nM LysoTracker Red DND-99 fluorescent dye (Invitrogen).
siRNAs
All siRNAs were chemically synthesized as stealth RNAi from Invitrogen. A pool of four different siRNA per gene (1 scrambled control plus 18 risk genes associated with neurodegenerative disorders) were transfected into BV2 murine cells, for the initial screen. Validation of Tardbp knockdown was performed by using pool or single stealth siRNA oligos. Transfection complexes in technical triplicates were prepared in Opti-mem serum-free medium (Invitrogen) by mixing Lipofectamine 2000 (Invitrogen) and siRNAs (50 nM). BV2 cells were seeded at density of 2,500 cells per well, 24 hr prior the transfection, on 96-well plates coated with poly-D-lysin (Sigma-Aldrich).
Acute Isolation of Adult Microglia
Microglia from the brain of adult mice were acutely isolated according to slight modification of Cardona et al., 2006 . Briefly, mice were anaesthetized and perfused with saline solution. Brains were harvested and freed of meninges, then finely minced by scissors in digestion cocktail containing 0.4 mg/ml CollagenaseD (Roche, Rotkreuz, Switzerland) and 0.025U/ml DNaseI (Sigma) in HBSS. The cell suspension was incubated for 45 min on shaking, at 37 C, then filtered through 70mm nylon mesh and washed in HBSS. The pellet was resuspended in 37% isotonic Percoll (Sigma-Aldrich), then underlayed with 70% and overlayed with 30% isotonic Percoll solution. The gradient was spun at 600 g for 30 min at 18 C and afterward the microglia were collected from the 70%-37% interface, washed in HBSS and further processed for RNA isolation.
